Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV
ACTIVE_NOT_RECRUITING
Status
Conditions
Interventions
- BIOLOGICAL: 426c.Mod.Core-C4b 30 mcg
- BIOLOGICAL: 426c.Mod.Core-C4b 100 mcg
- BIOLOGICAL: 426c.Mod.Core-C4b 300 mcg
- OTHER: Placebo
- BIOLOGICAL: BG505
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
- [object Object]
- [object Object]